Testosterone Protocol
A physician-supervised program to restore testosterone to peak physiological levels through biomarker-guided therapy.
Male testosterone levels decline at approximately 1–2% per year after age 30. By 45, many men have levels 30–40% below their peak — experiencing fatigue, reduced libido, muscle loss, mood changes, and cognitive decline. Our testosterone protocol uses comprehensive biomarker assessment to determine the safest, most effective path: lifestyle optimization, peptide support, or hormone replacement therapy.
Uses
- Low testosterone (hypogonadism)
- Age-related androgen decline
- Sexual dysfunction
- Muscle mass loss (sarcopenia)
- Mood changes and depression
- Cognitive decline and brain fog
Benefits
- Restores libido and sexual function
- Increases lean muscle mass and strength
- Reduces visceral body fat
- Improves mood, confidence, and drive
- Enhances cognitive sharpness
- Improves bone density
How It Works (Mechanism)
Testosterone acts on androgen receptors throughout the body — in muscle (protein synthesis), brain (mood and cognition), bone (density), fat tissue (lipolysis), and the cardiovascular system. Our protocols begin with peptides that stimulate endogenous production (LH/FSH pathway) before considering exogenous hormones — preserving testicular function and fertility.
Dosage Protocol
Protocol is individualized based on blood work. Peptide-based: Kisspeptin 1–10 nmol/kg 2x weekly. HCG 500–1000 IU 2x weekly. If TRT required: testosterone cypionate or enanthate 100–200 mg/week. All under physician monitoring with quarterly blood work.
When to Expect Results
Libido and energy: 2–4 weeks. Mood and cognitive improvement: 4–6 weeks. Muscle and body composition changes: 8–16 weeks. Full hormonal stabilization: 3–6 months.
PT-141
A central nervous system peptide that enhances sexual desire and function in both men and women.
PT-141 (Bremelanotide) is a melanocortin agonist that acts directly on the brain — not the vascular system — to enhance sexual desire and arousal. This makes it uniquely different from PDE5 inhibitors like Viagra or Cialis, which only address erectile mechanics. PT-141 addresses the central nervous system's desire pathways, making it effective for both men and women.
Uses
- Hypoactive sexual desire disorder (HSDD)
- Female sexual dysfunction
- SSRI-induced sexual side effects
- Erectile dysfunction (central component)
- Hormonal sexual dysfunction
- Performance anxiety
Benefits
- Increases sexual desire and libido centrally
- Effective in both men and women
- Works independent of cardiovascular mechanism
- Addresses SSRI-induced sexual dysfunction
- Enhances arousal and sensation
- Approved by FDA for HSDD in premenopausal women (Vyleesi®)
How It Works (Mechanism)
PT-141 activates melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) in the hypothalamus and limbic system — brain regions governing sexual desire, arousal, and reward. This triggers a cascade of neurotransmitter releases (dopamine, oxytocin) that create the subjective experience of desire.
Dosage Protocol
Subcutaneous injection: 1–2 mg, 45–90 minutes before sexual activity. Begin with 0.5 mg to assess tolerance. Maximum frequency: 2–3 times per week.
When to Expect Results
Onset: 45–90 minutes after injection. Duration of effect: 6–12 hours. Some users report cumulative benefit with repeated use over 2–4 weeks.
All hormonal protocols require UAE licensed physician review, comprehensive blood work, and ongoing monitoring. Results vary by individual. These statements are for informational purposes and do not constitute medical advice.